---
title: Anticonvulsant (Antiepileptic) Drugs
type: content
phase: 1
status: complete
priority: high
tags: [anticonvulsants, antiepileptics, seizures, epilepsy, phenytoin, valproate, carbamazepine, lamotrigine, levetiracetam]
created: 2025-11-08
last_modified: 2025-11-08
---

# Anticonvulsant (Antiepileptic) Drugs

## Introduction

Anticonvulsant drugs, also called antiepileptic drugs (AEDs), are used to treat seizure disorders (epilepsy) and have numerous other indications including bipolar disorder, neuropathic pain, and migraine prophylaxis. Understanding their mechanisms, pharmacokinetics, and adverse effects is crucial for effective seizure control and minimizing toxicity.

## Classification

### By Generation

**First-Generation (Traditional)**:
- Phenytoin
- Carbamazepine
- Valproic acid
- Phenobarbital
- Primidone
- Ethosuximide

**Second-Generation (Newer)**:
- Lamotrigine
- Levetiracetam
- Topiramate
- Oxcarbazepine
- Gabapentin
- Pregabalin
- Tiagabine
- Vigabatrin
- Zonisamide
- Felbamate

**Third-Generation (Newest)**:
- Lacosamide
- Perampanel
- Eslicarbazepine
- Brivaracetam
- Cannabidiol (Epidiolex)

### By Mechanism

**Sodium Channel Blockers**:
- Phenytoin, carbamazepine, lamotrigine, oxcarbazepine, lacosamide

**GABA Enhancement**:
- Benzodiazepines, barbiturates, vigabatrin, tiagabine

**Calcium Channel Blockers**:
- Ethosuximide, gabapentin, pregabalin

**Multiple Mechanisms**:
- Valproic acid, topiramate, zonisamide

**Unknown/Unique**:
- Levetiracetam, brivaracetam

---

## General Principles

### Mechanisms of Action

**Three Main Strategies**:

1. **Enhance inhibition** (↑GABA):
   - Direct GABA-A agonists (benzodiazepines, barbiturates)
   - ↓GABA metabolism (vigabatrin - MAO-B inhibitor)
   - ↑GABA release (gabapentin, pregabalin)

2. **Reduce excitation**:
   - **Na+ channel blockade** (phenytoin, carbamazepine, lamotrigine)
     - Stabilize inactive state of channel
     - ↓Repetitive firing
   - **Ca2+ channel blockade** (ethosuximide - T-type)
   - **Glutamate antagonism** (topiramate, perampanel)

3. **Multiple mechanisms**:
   - Valproic acid, topiramate, zonisamide

### Therapeutic Considerations

**Seizure Type Specificity**:
- Some drugs effective for specific seizure types
- Some drugs can worsen certain seizures (e.g., carbamazepine worsens absence)

**Monotherapy vs. Polytherapy**:
- **Monotherapy preferred** (fewer side effects, drug interactions)
- **Polytherapy** if seizures refractory to monotherapy

**Drug Selection Factors**:
- Seizure type
- Efficacy
- Side effect profile
- Drug interactions
- Cost
- Patient factors (age, comorbidities, pregnancy)

**Monitoring**:
- **Therapeutic drug monitoring** (TDM) for some drugs (phenytoin, carbamazepine, valproic acid)
- Monitor for efficacy and toxicity

---

## First-Generation Anticonvulsants

### Phenytoin (Dilantin)

**Mechanism**: Voltage-gated **sodium channel blocker**
- Binds to inactive state → prolongs inactivation
- ↓High-frequency repetitive firing
- **Use-dependent blockade** (more effective on rapidly firing neurons)

**Pharmacokinetics**:

**Absorption**:
- Oral, IV (fosphenytoin - prodrug)
- Slow, variable absorption (especially with food)
- **Extended-release** formulations available

**Distribution**:
- High protein binding (90% albumin)
- **Free phenytoin** is active (important in hypoalbuminemia, uremia)

**Metabolism**:
- Hepatic (CYP2C9, CYP2C19)
- **Zero-order kinetics** at therapeutic doses (saturable)
  - Small dose ↑→ large ↑in levels (non-linear)
  - Unpredictable dose-response

**Excretion**: Renal (metabolites)

**Half-life**: 12-36 hours (dose-dependent due to saturation)

**Therapeutic Range**: 10-20 mcg/mL (free: 1-2 mcg/mL)

**Clinical Uses**:
1. **Focal (partial) seizures**
2. **Generalized tonic-clonic seizures**
3. **Status epilepticus** (IV fosphenytoin preferred)
4. **NOT effective**: Absence, myoclonic (may worsen)
5. Trigeminal neuralgia (off-label)
6. Arrhythmias (digoxin toxicity - historical)

**Adverse Effects**:

**Dose-Related (Acute)**:
- **Nystagmus** (20 mcg/mL): First sign of toxicity
- **Ataxia** (30 mcg/mL)
- **Slurred speech, confusion** (40 mcg/mL)
- **Lethargy, coma** (>50 mcg/mL)
- CNS: Dizziness, drowsiness, headache
- **Cerebellar syndrome** (chronic toxicity - irreversible)

**Chronic Effects**:
- **Gingival hyperplasia** (50%):
  - Mechanism: ↑fibroblast activity, collagen synthesis
  - Good oral hygiene reduces risk
- **Hirsutism** (excess hair growth)
- **Coarsening of facial features**
- **Peripheral neuropathy**
- **Osteoporosis** (↑vitamin D metabolism)
- **Megaloblastic anemia** (folate deficiency)
- **Cognitive impairment** (chronic)

**Idiosyncratic**:
- **Hypersensitivity syndrome** (DRESS):
  - Drug reaction with eosinophilia and systemic symptoms
  - Rash, fever, lymphadenopathy, hepatitis, eosinophilia
  - Usually 2-8 weeks after starting
  - Associated with HLA-B*1502 (Asian populations - screen before use)
- **Stevens-Johnson syndrome (SJS)/TEN**
- **Hepatotoxicity**
- **Blood dyscrasias**: Aplastic anemia, agranulocytosis (rare)

**Teratogenicity**:
- **Fetal hydantoin syndrome**:
  - Craniofacial abnormalities, cleft lip/palate
  - Nail/digit hypoplasia
  - Neural tube defects
  - **Category D** - use only if benefits outweigh risks

**IV Administration**:
- **Fosphenytoin preferred** (water-soluble prodrug):
  - Faster infusion (150 mg PE/min vs 50 mg/min)
  - Less infusion site reactions
  - Safer IM
- **Phenytoin IV**: Risk of "purple glove syndrome" (extravasation → necrosis)

**Drug Interactions** (extensive):

**Phenytoin is inducer and substrate**:
- **CYP inducer**: ↓Levels of oral contraceptives, warfarin, many drugs
- **Affected by CYP inhibitors/inducers**:
  - Inhibitors (fluconazole, isoniazid, valproate) → ↑phenytoin levels
  - Inducers (rifampin, carbamazepine) → ↓phenytoin levels

**Protein binding displacement**:
- Valproate, aspirin → ↑free phenytoin (↑toxicity despite normal total level)

**Dosing**:
- Loading: 15-20 mg/kg IV (fosphenytoin) for status epilepticus
- Maintenance: 300-400 mg/day (divided or once-daily ER)
- **Adjust based on levels** (zero-order kinetics)

**Monitoring**:
- **Therapeutic drug monitoring** (TDM) essential
- Measure **free phenytoin** if hypoalbuminemia, uremia, pregnancy
- Monitor CBC, LFTs

**Clinical Pearls**:
- **Zero-order kinetics** → small dose changes can cause large level changes
- **Check free phenytoin** in hypoalbuminemia (formula: Corrected phenytoin = measured / (0.2 × albumin + 0.1))
- **Fosphenytoin for IV use** (safer)
- **Screen HLA-B*1502** in Asians before starting
- **Multiple drug interactions** - review medication list

### Carbamazepine (Tegretol)

**Mechanism**: Voltage-gated **sodium channel blocker** (similar to phenytoin)

**Pharmacokinetics**:

**Absorption**:
- Oral (IR, ER, suspension)
- Slow, erratic absorption

**Metabolism**:
- Hepatic (CYP3A4)
- **Autoinduction**: Induces own metabolism (levels ↓over 3-5 weeks)
- Active metabolite: Carbamazepine-10,11-epoxide (contributes to efficacy and toxicity)

**Half-life**: 12-17 hours initially → 8-12 hours (after autoinduction)

**Therapeutic Range**: 4-12 mcg/mL

**Clinical Uses**:
1. **Focal (partial) seizures** (first-line)
2. **Generalized tonic-clonic seizures**
3. **NOT effective**: Absence, myoclonic (may worsen)
4. **Trigeminal neuralgia** (FDA-approved, first-line)
5. **Bipolar disorder** (mood stabilizer)
6. Neuropathic pain

**Adverse Effects**:

**Common**:
- **Hyponatremia (SIADH)** (10-15%):
  - Dose-related
  - Monitor sodium, especially elderly
- CNS: Dizziness, ataxia, drowsiness, diplopia
- GI: Nausea, vomiting
- **Rash** (10%)

**Serious**:
- **Aplastic anemia** (rare, 1:200,000):
  - Fatal
  - Monitor CBC regularly
- **Agranulocytosis**
- **Stevens-Johnson syndrome (SJS)/TEN**:
  - Associated with **HLA-B*1502** (Asians) - **screen before use**
- **Hepatotoxicity**
- **Teratogenicity**: Neural tube defects (Category D)

**Drug Interactions**:
- **Strong CYP3A4 inducer**:
  - ↓Levels of oral contraceptives, warfarin, many drugs
  - Contraceptive failure common
- **CYP3A4 substrate**:
  - Inhibitors (ketoconazole, grapefruit juice) → ↑carbamazepine levels
  - Inducers (rifampin) → ↓levels

**Dosing**:
- Start: 200 mg BID
- Titrate slowly (autoinduction)
- Usual: 800-1200 mg/day (divided BID-QID)

**Monitoring**:
- **CBC** (baseline, periodic - watch for aplastic anemia)
- **LFTs**
- **Sodium** (hyponatremia)
- **Drug levels** (TDM)
- **Screen HLA-B*1502** in Asians

**Clinical Pearls**:
- **Autoinduction** → levels ↓over first weeks (may need dose ↑)
- **Screen HLA-B*1502** in Asians (SJS/TEN risk)
- **First-line for trigeminal neuralgia**
- **Monitor CBC** (aplastic anemia risk)
- **Oral contraceptive failure** (use barrier method)

### Valproic Acid (Depakote, Depakene)

**Mechanism**: **Multiple mechanisms**
1. **Na+ channel blockade** (high-frequency firing)
2. **↑GABA** (inhibits GABA transaminase)
3. **T-type Ca2+ channel blockade**
4. **Histone deacetylase inhibition**

**Pharmacokinetics**:

**Formulations**:
- Valproic acid (Depakene)
- Sodium valproate
- **Divalproex sodium** (Depakote - enteric coated, better tolerated)

**Absorption**: Oral, IV

**Metabolism**: Hepatic (multiple pathways)

**Protein Binding**: High (90%) - displaces other drugs

**Half-life**: 9-16 hours

**Therapeutic Range**: 50-100 mcg/mL (higher for bipolar: 50-125)

**Clinical Uses**:
1. **Broad-spectrum anticonvulsant**:
   - Focal seizures
   - **Generalized seizures** (tonic-clonic, absence, myoclonic)
   - **Drug of choice for generalized epilepsies**
2. **Bipolar disorder** (mania, maintenance)
3. **Migraine prophylaxis** (FDA-approved)

**Advantages**:
- **Broad spectrum** (effective for multiple seizure types)
- **IV formulation** available

**Adverse Effects**:

**Common**:
- **GI upset**: Nausea, vomiting, dyspepsia (use enteric-coated)
- **Tremor** (dose-related)
- **Weight gain** (significant)
- **Hair loss** (transient, regrows)
- Sedation, dizziness

**Metabolic**:
- **Hyperammonemia** (with or without encephalopathy)
  - Mechanism: ↓carbamoyl phosphate synthetase
  - Can occur at therapeutic levels
  - Lethargy, confusion, vomiting
- **Thrombocytopenia** (dose-related)
  - Usually mild, reversible
- **Pancreatitis** (rare but serious)

**Serious**:
- **Hepatotoxicity** (rare, <1:40,000):
  - **Fatal hepatic failure** (especially children <2 years)
  - Risk factors: Age <2, polytherapy, metabolic disorders
  - Usually within first 6 months
  - Monitor LFTs
- **Teratogenicity** (highest risk of all AEDs):
  - **Neural tube defects** (1-2% - spina bifida)
  - **Fetal valproate syndrome**: Facial abnormalities, limb defects, cardiac, cognitive impairment
  - **Category X** in pregnancy for migraine
  - **Category D** for epilepsy (avoid if possible, use lowest effective dose + folate)
- **PCOS** (polycystic ovarian syndrome) in women:
  - Hyperandrogenism, menstrual irregularities

**Drug Interactions**:
- **Displaces protein-bound drugs**: ↑Free levels of phenytoin, warfarin
- **Inhibits metabolism**: ↑Phenobarbital, lamotrigine levels (↓lamotrigine dose 50%)
- **Aspirin**: ↑Free valproate (toxicity risk)

**Dosing**:
- Start: 250-500 mg BID
- Usual: 1000-2000 mg/day (divided BID-TID)
- Max: 60 mg/kg/day

**Monitoring**:
- **LFTs** (baseline, frequent first 6 months)
- **CBC** (thrombocytopenia)
- **Ammonia** (if encephalopathy)
- **Drug levels** (TDM)

**Contraindications**:
- **Pregnancy** (especially first trimester) - avoid if possible
- Hepatic disease
- Mitochondrial disorders (urea cycle defects)
- **Women of childbearing age** (use with extreme caution, counsel on risks)

**Clinical Pearls**:
- **Broad spectrum** - good for multiple seizure types, especially generalized
- **Highest teratogenicity** - **avoid in pregnancy** if possible
- **Monitor LFTs** closely first 6 months (hepatotoxicity risk)
- **Divalproex** (Depakote) better tolerated than valproic acid
- **Check ammonia** if encephalopathy develops
- **Reduce lamotrigine dose 50%** if adding valproate

### Phenobarbital

**Mechanism**: **GABA-A receptor agonist**
- Binds to barbiturate site on GABA-A receptor
- ↑Duration of chloride channel opening (vs. benzodiazepines ↑frequency)
- Can directly activate channel (no ceiling effect → respiratory depression)

**Pharmacokinetics**:
- Oral, IV, IM
- Long half-life: 80-120 hours
- Hepatic metabolism, renal excretion
- **CYP inducer** (strong)

**Therapeutic Range**: 15-40 mcg/mL

**Clinical Uses**:
1. **Generalized tonic-clonic seizures**
2. **Focal seizures**
3. **Neonatal seizures** (drug of choice)
4. **Status epilepticus** (third-line)

**Advantages**:
- **Inexpensive**
- Long half-life (once-daily dosing)
- IV formulation

**Adverse Effects**:
- **Sedation** (major limitation)
- **Cognitive impairment** (especially children)
- **Behavioral changes**: Hyperactivity (children), depression
- Tolerance, physical dependence
- **Respiratory depression** (overdose - no ceiling effect)
- Rash (rare - Stevens-Johnson syndrome)
- **Teratogenicity**: Fetal hydantoin-like syndrome

**Drug Interactions**:
- **Strong CYP inducer**: ↓Levels of many drugs (oral contraceptives, warfarin)

**Dosing**:
- 1-3 mg/kg/day (usually 60-180 mg/day)

**Clinical Pearls**:
- **Cheap, effective** but sedating
- **Drug of choice for neonatal seizures**
- **Largely replaced by newer AEDs** (sedation, cognitive effects)
- **Strong inducer** - many drug interactions

### Ethosuximide (Zarontin)

**Mechanism**: **T-type calcium channel blocker**
- Blocks thalamic T-type Ca2+ channels
- Prevents thalamocortical oscillations (3 Hz spike-wave)

**Pharmacokinetics**:
- Oral
- Half-life: 40-50 hours (children), 60 hours (adults)
- Hepatic metabolism

**Therapeutic Range**: 40-100 mcg/mL

**Clinical Uses**:
1. **Absence seizures** (first-line, highly specific)
2. **NOT effective for other seizure types**

**Adverse Effects**:
- GI upset (nausea, vomiting)
- Drowsiness, fatigue
- Headache, dizziness
- Rash, SJS (rare)
- Blood dyscrasias (rare)

**Dosing**:
- Children: 15-40 mg/kg/day
- Adults: 500-1500 mg/day (divided BID)

**Clinical Pearl**: **Drug of choice for absence seizures** (very specific indication)

---

## Second-Generation Anticonvulsants

### Lamotrigine (Lamictal)

**Mechanism**:
- **Voltage-gated sodium channel blocker**
- **Glutamate release inhibition**

**Pharmacokinetics**:
- Oral
- Half-life: 25-30 hours (monotherapy)
- Hepatic metabolism (glucuronidation)
- **Half-life affected by other drugs**:
  - **Valproate ↑half-life 2x** (inhibits metabolism) → reduce lamotrigine dose 50%
  - **CYP inducers ↓half-life** (phenytoin, carbamazepine) → increase lamotrigine dose

**Clinical Uses**:
1. **Focal seizures**
2. **Generalized tonic-clonic seizures**
3. **Absence seizures** (children - alternative to ethosuximide)
4. **Bipolar disorder** (maintenance, depression) - FDA-approved
5. Lennox-Gastaut syndrome

**Advantages**:
- **Broad spectrum**
- **Well-tolerated** (minimal cognitive/sedative effects)
- **No weight gain** (may cause weight loss)
- Effective for bipolar depression

**Adverse Effects**:

**Common**:
- Headache, dizziness
- Nausea, vomiting
- Insomnia
- Diplopia (blurred/double vision)

**Serious**:
- **Rash** (10%):
  - Usually benign maculopapular rash
  - **Risk of SJS/TEN** (0.1% adults, 1% children):
    - Life-threatening
    - Risk factors: Rapid titration, high starting dose, valproate (↑levels)
    - **Prevention**: **Slow titration** (essential)
  - **Hypersensitivity syndrome** (DRESS)

**Dosing** (SLOW TITRATION essential):

**Without Valproate**:
- Weeks 1-2: 25 mg/day
- Weeks 3-4: 50 mg/day
- Week 5+: ↑by 50 mg q1-2 weeks
- Target: 200-400 mg/day (divided BID)

**With Valproate** (↓dose 50%):
- Weeks 1-2: 12.5 mg every other day (or 25 mg/day)
- Weeks 3-4: 25 mg/day
- Week 5+: ↑by 25 mg q1-2 weeks
- Target: 100-200 mg/day

**With CYP Inducers** (↑dose):
- Start: 50 mg/day
- Faster titration

**Monitoring**:
- **Watch for rash** (especially first 8 weeks)
- **Stop immediately if rash develops**

**Drug Interactions**:
- **Valproate**: ↑Lamotrigine levels 2x → **reduce lamotrigine dose 50%**
- CYP inducers (phenytoin, carbamazepine): ↓Lamotrigine levels → increase dose

**Clinical Pearls**:
- **Slow titration essential** to prevent SJS/TEN
- **Reduce dose 50% if on valproate**
- **Stop immediately if rash** (cannot distinguish benign from SJS early)
- **Well-tolerated** - minimal cognitive effects, no weight gain
- **Good for bipolar depression** (FDA-approved)

### Levetiracetam (Keppra)

**Mechanism**: Binds to **SV2A** (synaptic vesicle protein 2A)
- Unique mechanism
- Modulates neurotransmitter release

**Pharmacokinetics**:
- Oral, IV
- **Minimal metabolism** (66% renally excreted unchanged)
- **No CYP interactions**
- Half-life: 6-8 hours

**Clinical Uses**:
1. **Focal seizures** (adjunct and monotherapy)
2. **Generalized tonic-clonic seizures**
3. **Myoclonic seizures**
4. **Status epilepticus** (off-label)

**Advantages**:
- **Excellent tolerability**
- **No drug interactions** (not metabolized by CYP)
- **No monitoring required** (no TDM needed)
- **Rapid titration** possible
- **IV formulation** (bioequivalent to oral)
- **Broad spectrum**

**Adverse Effects**:

**Common**:
- Somnolence, fatigue
- Dizziness
- Asthenia (weakness)

**Psychiatric** (10-15%):
- **Irritability, aggression, mood changes**
- Depression, anxiety
- Psychosis (rare)
- **More common with history of psychiatric illness**

**Dosing**:
- Start: 500 mg BID
- Can start at full dose (no need for slow titration)
- Usual: 1000-1500 mg BID
- Max: 3000 mg/day
- **Renal adjustment required** (excreted unchanged)

**Monitoring**: None required (no TDM, no labs)

**Clinical Pearls**:
- **Excellent choice for many patients** (efficacy, tolerability, no interactions)
- **No drug interactions** - safe with other medications
- **No monitoring required** - convenient
- **Watch for behavioral changes** (irritability, aggression)
- **Rapid titration** possible (unlike lamotrigine)
- **IV = PO bioequivalence** (can switch easily)

### Topiramate (Topamax)

**Mechanism**: **Multiple mechanisms**
1. Na+ channel blockade
2. GABA-A enhancement
3. Glutamate (AMPA/kainate) antagonism
4. Carbonic anhydrase inhibition

**Pharmacokinetics**:
- Oral
- Partial renal excretion (70% unchanged), partial hepatic
- Half-life: 21 hours
- Weak CYP inducer (high doses)

**Clinical Uses**:
1. **Focal seizures**
2. **Generalized tonic-clonic seizures**
3. Lennox-Gastaut syndrome
4. **Migraine prophylaxis** (FDA-approved)
5. **Weight loss** (off-label - Qsymia = topiramate + phentermine)

**Advantages**:
- **Broad spectrum**
- **Weight loss** (unique among AEDs)
- Migraine prophylaxis

**Adverse Effects**:

**Common**:
- **Cognitive impairment** (dose-related):
  - "Dopamax" - word-finding difficulty, memory problems, confusion
  - **Limiting side effect**
- **Paresthesias** (tingling hands/feet - carbonic anhydrase inhibition)
- **Weight loss** (can be advantage or disadvantage)
- Fatigue, dizziness
- Anorexia, taste alteration

**Serious**:
- **Kidney stones** (1-2%):
  - Carbonic anhydrase inhibition → ↓urine citrate, ↑urine pH
  - Calcium phosphate stones
  - Hydration important
- **Metabolic acidosis**:
  - Non-anion gap (hyperchloremic)
  - Monitor bicarbonate
- **Acute angle-closure glaucoma** (rare):
  - Onset within 1 month
  - Myopia, eye pain
  - Ophthalmology emergency
- **Oligohydrosis** (↓sweating) and hyperthermia:
  - Especially children
  - Risk in hot weather
- **Teratogenicity**: Cleft lip/palate, hypospadias (Category D)

**Dosing**:
- **Slow titration required** (cognitive effects):
  - Start: 25 mg qhs
  - ↑by 25-50 mg weekly
  - Usual: 200-400 mg/day (divided BID)
  - Max: 400-600 mg/day

**Monitoring**:
- Bicarbonate (metabolic acidosis)
- Kidney function

**Drug Interactions**:
- **↓Efficacy of oral contraceptives** (at high doses >200 mg/day)

**Clinical Pearls**:
- **Cognitive side effects limiting** ("Dopamax")
- **Slow titration essential** (reduce cognitive effects)
- **Weight loss** - good for overweight patients, concern for underweight
- **Good for migraine prophylaxis**
- **Hydration important** (kidney stone risk)
- **Monitor for angle-closure glaucoma** (first month)

### Oxcarbazepine (Trileptal)

**Mechanism**: Voltage-gated **sodium channel blocker** (like carbamazepine)

**Relationship**: Keto-analog of carbamazepine
- Similar efficacy
- **Better tolerability** (less enzyme induction, fewer drug interactions)

**Pharmacokinetics**:
- Oral
- **Prodrug** → active metabolite (monohydroxy derivative)
- Half-life: 9 hours (metabolite)
- Minimal CYP induction (less than carbamazepine)

**Clinical Uses**:
1. **Focal seizures** (monotherapy and adjunct)
2. **Generalized tonic-clonic seizures**
3. Trigeminal neuralgia (off-label)
4. Bipolar disorder (off-label)

**Advantages vs. Carbamazepine**:
- **Fewer drug interactions** (less enzyme induction)
- **Better tolerability**
- **No autoinduction**
- Lower risk of serious idiosyncratic reactions (aplastic anemia, agranulocytosis)

**Adverse Effects**:

**Common**:
- **Hyponatremia** (25-30%):
  - **More common than carbamazepine**
  - Dose-related
  - Monitor sodium, especially elderly
- Dizziness, somnolence
- Headache, ataxia
- Nausea, vomiting
- Diplopia

**Serious**:
- **Cross-reactivity with carbamazepine** (25-30%):
  - If allergic to carbamazepine → may react to oxcarbazepine
- SJS/TEN (rare):
  - HLA-B*1502 association (screen Asians)

**Dosing**:
- Start: 300 mg BID
- Usual: 600-1200 mg BID
- Max: 2400 mg/day

**Drug Interactions**:
- **Less than carbamazepine** but still induces some
- **↓Oral contraceptive efficacy** (use backup method)

**Monitoring**:
- **Sodium** (baseline, periodic - hyponatremia risk)

**Clinical Pearls**:
- **Better alternative to carbamazepine** (similar efficacy, better tolerability)
- **Monitor sodium** (higher hyponatremia risk than carbamazepine)
- **Cross-reactivity 25%** if carbamazepine allergy
- **Screen HLA-B*1502** in Asians

### Gabapentin (Neurontin)

**Mechanism**: Binds to **α2δ subunit** of voltage-gated calcium channels
- ↓Calcium influx → ↓neurotransmitter release
- Despite name, does NOT act on GABA receptors

**Pharmacokinetics**:
- Oral
- **Not metabolized** (renally excreted unchanged)
- **No protein binding**
- **No CYP interactions**
- Half-life: 5-7 hours
- **Non-linear absorption**: ↑Dose → ↓bioavailability (saturated transporter)

**Clinical Uses**:
1. **Focal seizures** (adjunct)
2. **Neuropathic pain** (diabetic neuropathy, postherpetic neuralgia) - FDA-approved
3. Restless legs syndrome (off-label)
4. Anxiety (off-label)
5. Hot flashes (off-label)

**Advantages**:
- **Excellent tolerability**
- **No drug interactions**
- **No monitoring required**
- Safe in hepatic disease
- Multiple non-seizure uses

**Adverse Effects**:
- **Somnolence, dizziness** (common, dose-related)
- **Weight gain**
- Peripheral edema
- Ataxia
- **Abuse potential** (emerging - euphoria in some, especially with opioid history)

**Dosing**:
- Start: 300 mg qhs
- Titrate: ↑300 mg q1-3 days
- Usual: 900-1800 mg/day (divided TID)
- Max: 3600 mg/day
- **Renal adjustment required**

**Clinical Pearls**:
- **Excellent for neuropathic pain** (FDA-approved)
- **No drug interactions** - safe with other medications
- **TID dosing** (short half-life, saturable absorption)
- **Renal excretion** - adjust in renal impairment
- **Abuse potential emerging** (monitor in patients with substance abuse history)

### Pregabalin (Lyrica)

**Mechanism**: Like gabapentin - binds **α2δ subunit** of calcium channels

**Advantages over Gabapentin**:
- **Linear pharmacokinetics** (better bioavailability at higher doses)
- **BID dosing** (vs. TID)
- Faster titration

**Pharmacokinetics**:
- Oral
- Renally excreted unchanged
- Half-life: 6 hours

**Clinical Uses**:
1. **Focal seizures** (adjunct)
2. **Neuropathic pain** (diabetic neuropathy, postherpetic neuralgia) - FDA-approved
3. **Fibromyalgia** (FDA-approved)
4. Generalized anxiety disorder (FDA-approved in Europe, not US)

**Adverse Effects**: Similar to gabapentin
- Dizziness, somnolence
- Weight gain
- Peripheral edema
- Controlled substance (Schedule V) - abuse potential

**Dosing**:
- Start: 75 mg BID or 150 mg qhs
- Usual: 150-300 mg BID
- Max: 600 mg/day

**Clinical Pearls**:
- **Better pharmacokinetics than gabapentin** (linear, BID dosing)
- **Good for neuropathic pain and fibromyalgia**
- **Schedule V** - controlled substance (abuse potential)

---

## Third-Generation Anticonvulsants

### Lacosamide (Vimpat)

**Mechanism**: **Slow inactivation of sodium channels** (different from other Na+ blockers)

**Clinical Uses**:
1. Focal seizures (adjunct and monotherapy)

**Advantages**:
- Unique mechanism
- IV formulation

**Adverse Effects**:
- Dizziness, ataxia
- **PR prolongation** (cardiac conduction):
  - Caution in heart block, cardiac disease
  - Baseline ECG recommended

**Dosing**: 200-400 mg/day (divided BID)

**Clinical Pearl**: **Cardiac monitoring** recommended (PR prolongation)

---

## Special Topics

### Status Epilepticus Treatment

**Definition**: Seizure >5 minutes or recurrent seizures without recovery

**Treatment Protocol**:

**First-line** (0-5 minutes):
1. **Benzodiazepines** (immediate):
   - Lorazepam 4 mg IV (preferred)
   - Diazepam 10 mg IV or 20 mg rectal
   - Midazolam 10 mg IM (if no IV access)

**Second-line** (5-20 minutes) - if seizures persist:
2. **Fosphenytoin** 20 mg PE/kg IV (preferred over phenytoin)
   - OR **Valproate** 40 mg/kg IV
   - OR **Levetiracetam** 60 mg/kg IV (up to 4500 mg)

**Third-line** (>20 minutes) - refractory status epilepticus:
3. **Phenobarbital** 15 mg/kg IV
   - OR general anesthesia (propofol, midazolam, pentobarbital)
   - ICU, intubation, EEG monitoring

**Clinical Pearl**: **Lorazepam preferred first-line** (longer duration than diazepam in brain)

### Antiepileptic Drug Selection by Seizure Type

**Focal (Partial) Seizures**:
- First-line: Levetiracetam, lamotrigine, carbamazepine, oxcarbazepine
- Alternatives: Phenytoin, topiramate, gabapentin, pregabalin, lacosamide

**Generalized Tonic-Clonic**:
- First-line: **Valproate** (broad spectrum), levetiracetam, lamotrigine
- Alternatives: Topiramate, phenytoin, carbamazepine (if secondary generalized)

**Absence Seizures**:
- First-line: **Ethosuximide**, **valproate**
- Alternative: Lamotrigine
- **Avoid**: Carbamazepine, phenytoin, gabapentin (may worsen)

**Myoclonic Seizures**:
- First-line: **Valproate**, levetiracetam
- **Avoid**: Carbamazepine, phenytoin, gabapentin (may worsen)

**Lennox-Gastaut Syndrome** (mixed seizures):
- Valproate, lamotrigine, topiramate, rufinamide, felbamate

### Pregnancy and Anticonvulsants

**Risks**:
- **All AEDs are teratogenic** to varying degrees
- Maternal seizures also harmful (hypoxia, trauma)
- Risk-benefit assessment required

**Teratogenic Risks** (highest to lowest):
1. **Valproate** (highest - avoid if possible):
   - Neural tube defects (1-2%)
   - Fetal valproate syndrome
   - Cognitive impairment
2. Phenobarbital, phenytoin: Fetal hydantoin syndrome
3. Carbamazepine: Neural tube defects
4. Topiramate: Cleft lip/palate
5. Lamotrigine: Relatively safer (still Category C)
6. Levetiracetam: Limited data, appears safer

**Management**:
- **Preconception counseling** essential
- **Switch to safer AED** before pregnancy if possible
- **Monotherapy preferred** (lower risk than polytherapy)
- **Lowest effective dose**
- **Folate supplementation** (5 mg/day) - reduces neural tube defect risk
- **Vitamin K** in last month (phenytoin, phenobarbital, carbamazepine) - prevent neonatal hemorrhage
- **Continue AED during pregnancy** (seizure risk > AED risk usually)

**Preferred AEDs in Pregnancy**:
- Levetiracetam, lamotrigine (relatively safer)
- **Avoid valproate** if possible (especially first trimester)

### Therapeutic Drug Monitoring (TDM)

**Indications for TDM**:
1. Narrow therapeutic window drugs
2. Non-linear pharmacokinetics
3. Significant inter-patient variability
4. Suspected non-adherence
5. Drug interactions
6. Pregnancy (levels may ↓)
7. Toxicity symptoms

**AEDs Requiring TDM**:
- **Phenytoin** (essential - zero-order kinetics)
- **Carbamazepine**
- **Valproic acid**
- Phenobarbital
- Primidone

**AEDs NOT Requiring Routine TDM**:
- Levetiracetam, lamotrigine, topiramate, gabapentin, pregabalin (dose to clinical effect)

---

## Clinical Pearls

1. **Monotherapy preferred** - fewer side effects, interactions
2. **Start low, go slow** - most AEDs require titration
3. **Lamotrigine: Slow titration essential** - prevent SJS/TEN
4. **Valproate highest teratogenicity** - avoid in women of childbearing age
5. **Levetiracetam: No interactions, no monitoring** - convenient
6. **Phenytoin: Zero-order kinetics** - small dose changes → large level changes
7. **Carbamazepine: Autoinduction** - levels ↓over first weeks
8. **Screen HLA-B*1502** in Asians before carbamazepine/phenytoin/oxcarbazepine
9. **Monitor sodium** with carbamazepine, oxcarbazepine (hyponatremia)
10. **Topiramate: Cognitive effects** ("Dopamax") - slow titration
11. **Status epilepticus: Lorazepam first-line**, then fosphenytoin/valproate/levetiracetam
12. **Ethosuximide for absence seizures** - highly specific
13. **Never stop AEDs abruptly** - seizure risk (taper over weeks to months)

---

## Key Takeaways

1. **Mechanisms**: Na+ channel blockade, GABA enhancement, Ca2+ channel blockade, multiple
2. **Phenytoin**: Na+ blocker, zero-order kinetics, TDM essential, many interactions
3. **Carbamazepine**: Na+ blocker, autoinduction, HLA-B*1502 screening (Asians), hyponatremia
4. **Valproate**: Broad spectrum, highest teratogenicity, hepatotoxicity risk, TDM
5. **Lamotrigine**: Broad spectrum, slow titration (SJS/TEN risk), reduce dose 50% with valproate
6. **Levetiracetam**: Unique mechanism (SV2A), no interactions, no monitoring, behavioral effects
7. **Topiramate**: Multiple mechanisms, cognitive effects, weight loss, kidney stones
8. **Ethosuximide**: T-type Ca2+ blocker, absence seizures only
9. **Status epilepticus**: Lorazepam → fosphenytoin/valproate/levetiracetam → phenobarbital/anesthesia
10. **Pregnancy**: All AEDs teratogenic, valproate worst (avoid), levetiracetam/lamotrigine relatively safer
11. **TDM**: Phenytoin, carbamazepine, valproate require monitoring
12. **Never stop abruptly**: Seizure risk - gradual taper required

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
3. American Academy of Neurology Practice Guidelines for Epilepsy
4. Glauser T, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013.
5. FDA Drug Safety Communications - Antiepileptic Drugs
6. Harden CL, et al. Practice parameter update: management issues for women with epilepsy - focus on pregnancy. Neurology. 2009.
